HR+/HER2– de novo metastatic breast cancer:
a true peculiar entity?

Rosalba Torrisi, Flavia Jacobs, Chiara Miggiano, Rita De Sanctis, Armando Santoro

Article Type



This is a critical narrative review focusing on HR+/human epidermal growth factor receptor 2-negative (HER2–) de novo metastatic breast cancer in terms of genomic, biological, pathological, and clinical features and outcomes after systemic and locoregional treatments, outlining differences with recurrent metastatic breast cancer.

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.